CD36 and atherosclerosis: The therapeutic potential for improving the lesion stability by targeting CD36 with the cyclic azapeptide MPE-298 has now been investigated in a preclinical mouse model of atherosclerosis featuring apolipoprotein E-deficient (apoE−/−) mice fed a high-fat high-cholesterol (HFHC) diet.